ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

N1087

Its studies are mostly in Alopecia, led by Eurofarma Laboratorios.

Furthest: phase 3, since Dec 11, 20251 company-led study, 1 open or runningNext primary completion: Jul 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eurofarma Laboratorios11 open or runningphase 3since Dec 11, 2025Dec 11, 2025Jul 2028phase 3 · NCT07303322

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 11, 2025First study: phase 3 study in AlopeciaFirst studyNCT07303322 · 372 planned · Brazil

Ahead

  1. Jul 2028Primary completion: phase 3 study in AlopeciaNCT07303322

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07303322Alopecia · Brazil3Not yet recruitingJul 2028372

How it is read

Names in the registry

  • “N1087”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.